Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2024-10-09

Clinical Trial Update: A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Hidradenitis Suppurativa [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating spesolimab for hidradenitis suppurativa has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • SPESOLIMAB (BI655130)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Hidradenitis Suppurativa | Phase 2 | Status: COMPLETED | Results posted: 2024-10-09